EUVIMEDEUVIMED entdecken
Crossref

Aramchol interacts with regorafenib and ursodeoxycholic acid to kill cancer cells

Paul Dent, Michael R Booth, Laurence Booth, Jane L Roberts

Medical Research Archives · 2026

DOI: 10.18103/mra.2026.0818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Paul Dent und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Stearoyl-CoA desaturase (SCD1) inhibitor aramchol kills a diverse range of cancer cell types, alone or more so when combined with other oncology therapeutics. Aramchol concentrates in the liver and lipogenic tissues. The bile acid ursodeoxycholic acid (UDCA) and its taurine and glycine conjugated forms TUDCA and GUDCA, are hydrophilic secondary bile acids that concentrate in the liver and are used to treat liver diseases such as primary biliary cholangitis and other cholestatic diseases. We hypothesized that UDCA may interact with aramchol to kill tumor cell types that readily metastasize to the liver, particularly uveal melanoma (UM) a disease for which there are few effective therapies. Aramchol and the multi-kinase inhibitor regorafenib interacted to kill UM cells, an effect that was significantly enhanced by TUDCA but to a lesser extent by GUDCA, and ineffectually by unconjugated UDCA. The combination of aramchol with regorafenib strongly induced autophagosome formation, that was enhanced in all tumor cell types treated with TUDCA or GUDCA. Later, autolysosome formation was observed that was not significantly modified by TUDCA/GUDCA. Simultaneous knock down of Beclin1 and LAMP2 significantly reduced the formation of autophagosomes, autolysosomes and tumor cell death below those caused by knock down of Beclin1 alone. Knock down of SCD1 did not alter the amount of killing caused by [aramchol plus regorafenib], TUDCA/GUDCA or all agents in combination. Collectively, our in vitro preclinical data argues that UM located in the liver may therapeutically benefit from aramchol, regorafenib and UDCA treatment.

Zitieren

APA

Dent, P., Booth, M. R., Booth, L., & Roberts, J. L. (2026). Aramchol interacts with regorafenib and ursodeoxycholic acid to kill cancer cells. Medical Research Archives. https://doi.org/10.18103/mra.2026.0818

Vancouver

Dent P, Booth MR, Booth L, Roberts JL. Aramchol interacts with regorafenib and ursodeoxycholic acid to kill cancer cells. Medical Research Archives. 2026. doi:10.18103/mra.2026.0818

BibTeX
@article{Dent2026,
  author = {Dent, Paul and Booth, Michael R and Booth, Laurence and Roberts, Jane L},
  title = {Aramchol interacts with regorafenib and ursodeoxycholic acid to kill cancer cells},
  journal = {Medical Research Archives},
  year = {2026},
  doi = {10.18103/mra.2026.0818}
}
Kostenlos starten →